Lantheus (NASDAQ:LNTH) Shares Down 3%

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) dropped 3% on Thursday . The stock traded as low as $106.18 and last traded at $106.40. Approximately 200,581 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 1,045,297 shares. The stock had previously closed at $109.71.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several research analyst reports. JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Leerink Partners boosted their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Mizuho boosted their price target on Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, May 3rd. Finally, Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Lantheus currently has an average rating of "Moderate Buy" and a consensus target price of $119.00.

Lantheus Price Performance

The company has a market capitalization of $7.26 billion, a price-to-earnings ratio of 16.00 and a beta of 0.51. The company has a quick ratio of 4.55, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a 50 day simple moving average of $99.57 and a 200 day simple moving average of $79.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business's revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.40 earnings per share. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.46 EPS for the current year.

Insider Transactions at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares of the company's stock, valued at $4,990,171.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now directly owns 62,557 shares of the company's stock, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Insiders sold 41,193 shares of company stock valued at $3,949,202 over the last quarter. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Clearbridge Investments LLC raised its stake in Lantheus by 7.6% during the second quarter. Clearbridge Investments LLC now owns 560,609 shares of the medical equipment provider's stock valued at $45,011,000 after buying an additional 39,369 shares in the last quarter. Cetera Investment Advisers raised its stake in Lantheus by 34.8% during the second quarter. Cetera Investment Advisers now owns 29,592 shares of the medical equipment provider's stock valued at $2,376,000 after buying an additional 7,640 shares in the last quarter. Quarry LP raised its stake in Lantheus by 51.3% during the second quarter. Quarry LP now owns 1,145 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 388 shares in the last quarter. Creative Planning raised its stake in Lantheus by 48.5% during the second quarter. Creative Planning now owns 23,714 shares of the medical equipment provider's stock valued at $1,904,000 after buying an additional 7,742 shares in the last quarter. Finally, Mackenzie Financial Corp raised its stake in Lantheus by 259.2% during the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider's stock valued at $1,250,000 after buying an additional 11,236 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.